WeVote
Log In

Bill

Bill

SB 941

Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.

2025 Regular Session Introduced by Dusty Deevers

Oklahoma requires pharmaceutical manufacturers to publicly disclose complete product ingredient lists with penalties for non-compliance to improve consumer safety and medication awareness.

Second Reading referred to Health and Human Services
0
WeVote Research Nonpartisan
Bill Summary · SB 941

Legislative bill overview

SB 941 requires pharmaceutical manufacturers to publish complete ingredient lists for their products, with violations subject to administrative, civil, and criminal penalties. The bill is currently in early stages of the legislative process, having just completed first reading and been referred to the Health and Human Services committee.

Why is this important

Pharmaceutical transparency directly affects consumer ability to identify potential allergens, inactive ingredients, and drug interactions. Currently, while FDA regulations require ingredient disclosure to healthcare providers, consumer-facing labels may not always list all components, potentially impacting medication safety decisions for patients with allergies or sensitivities.

Potential points of contention

  • Regulatory overlap: Federal FDA already regulates pharmaceutical ingredient labeling; this state requirement could create conflicting standards or duplicate oversight
  • Trade secrets and intellectual property: Manufacturers may argue that full ingredient disclosure conflicts with proprietary formula protection and competitive interests
  • Enforcement mechanism: The bill establishes criminal penalties but provides minimal detail on enforcement authority, burden of proof, and whether penalties apply to manufacturers, distributors, or retailers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.